Statements Of Cash Flows (USD $)	12 Months Ended
	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010
Cash flows from operating activities
Net loss	$ (9,238,427)	$ (32,031,175)	$ (19,923,487)
Adjustments to reconcile net loss to cash used in operating activities:
Depreciation	1,300,188	1,462,238	1,697,694
Amortization	299,833	299,833	230,459
Amortization of warrants	2,977,119	1,331,549	1,652,672
Share-based compensation, value	2,293,731	2,487,441	2,049,606
Non-cash royalty (income), net		(2,353,718)	(3,381,424)
Gain/loss on debt conversion	(75,612)
Loss on asset disposal	12,444	86,278	5,039
Adjustment of warrants and debt conversion features	(8,189,895)	(3,416,383)	(600,816)
Interest due from issuance of stock	192,128
Changes in operating assets and liabilities:
Accounts receivable	(447,613)	2,811,531	(2,762,921)
Other receivables	19,534	28,495	65,175
Inventories	937,810	(594,576)	(1,075,075)
Prepaid expenses and other current assets	(760,474)	827,297	522,924
Other assets	7,773	(2,223)	(33,426)
Accounts payable	(2,053,493)	(3,186,001)	4,937,129
Accrued liabilities	(514,689)	(1,090,072)	(1,221,120)
Deferred revenue	1,125,079	1,775,856	(1,060,903)
Other liabilities	(3,094)	(5,648)	(11,271)
Net cash used in operating activities	(12,117,658)	(31,569,278)	(18,909,745)
Cash flows from investing activities
Purchase of equipment	(130,699)	(1,031,749)	(715,770)
Net cash used in investing activities	(130,699)	(1,031,749)	(715,770)
Cash flows from financing activities
Proceeds from term note			10,000,000
Payments of term note	(4,000,000)	(2,000,000)	(333,333)
Proceeds from revolving line of credit	54,806,154	77,109,376	58,034,809
Payments of revolving line of credit	(62,842,934)	(72,818,866)	(57,503,298)
Proceeds from convertible debt	7,738,351
Proceeds/Payments from Healthcare Royalty Partners debt	2,500,000	14,317,397
Payments of Healthcare Royalty Partners debt	(1,252,647)
Payments of Biosense Debt		(5,540,373)	(2,071,139)
Proceeds from issuance of stock and warrants, net of issuance costs	9,122,232	239,593	16,200,745
Net cash provided by financing activities	6,071,156	11,307,127	24,327,784
Net decrease in cash and cash equivalents	(6,177,201)	(21,293,900)	4,702,269
Cash and cash equivalents at beginning of period	13,954,919	35,248,819	30,546,550
Cash and cash equivalents at end of period	7,777,718	13,954,919	35,248,819
Supplemental disclosures of cash flow information
Interest Paid	$ 3,258,900	$ 859,494	$ 140,253